РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ ЗОЛЕДРОНОВОЙ КИСЛОТЫ В ЛЕЧЕНИИ ОСТЕОПОРОЗА

1. Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21: 1453-60.

2. Lo J.C., Pressman A.R., Omar M.A., Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-8.

3. Siris E.S., Harris S.T., Rosen C.J. et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22.

4. Huybrechts K.F., Ishak K.J., Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38: 922-8.

5. Nancollas G.H., Tang R., Gulde S., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone.38 (2006) 617-627

6. Rogers M.J., Frith J.C., Luckman P. et al. Molecular mechanisms of action of bisphosphonates. Bone. 1999;24(suppl):73S-79S.

7. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100.

8. Dunford J.E., Thompson K., Coxon F.P., et al. Structureactivity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242.

9. Green J.R., Müller K., Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res.1994;9:745-751.

10. Green J.R., Rogers M.J. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res. 2002;55:210-224.

11. Gasser J.A., Green J.R. Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats [abstract B16]. Bone. 2002;30 (3):41S.

12. Gasser J.A., Shen V., Leininger R. et al. Zoledronic acid administered as a single intravenous dose preserves mechanical properties and maintains cortical and cancellous bone structures in ovariectomized rats. Bone. 2003:32 (5 suppl 1):S79.

13. Glatt M., Pataki A., Evans G.P. et al. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int. 2004;15:707-715.

14. Reid I.R., Brown J.P., Burckhardt P. et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.

15. Black D.M., Delmas P.D., Eastell R. et al. Onceyearlyzol edronicacidfortreatmentofpostmenopausalosteoporosis N Engl J Med. 2007 May 3;356 (18):1809-22

16. Grbic J.T., Landesberg R., Lin S.Q. et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 2008 Jan;139 (1):32-40.

17. Recker R.R., Delmas P.D., Halse J. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008 Jan;23 (1):6-16.

18. Lyles K.W., Colón-Emeric C.S., Magaziner J.S. et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip FractureN Engl J Med. 2007;357.

19. Colón-Emeric C., Kuchibhatla M., Pieper C. et al. The contribution of hip fracture to risk of subsequent fracture: data from two longitudinal studies. Osteoporos Int 2003;14:879-83.

20. Gardner M.J., Brophy R.H., Demetrakopoulos D. et al. Interventions to improve osteoporosis treatment following hip fracture: a prospective, randomized trial. J Bone Joint Surg Am 2005;87:3-7.

21. Solomon D.H., Finkelstein J.S., Katz J.H., Mogun H., Avorn J. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 2003;115:398-400.